Joshua Weiyuan Wang Ph.D.

Joshua Weiyuan Wang, Ph.D., has a diverse and extensive work experience. Joshua Weiyuan is currently serving as the Founding CEO & President of VerImmune, a biotechnology company focused on developing a first-in-class cancer therapy named Anti-tumor Immune Redirection (AIR). Prior to this, they co-founded PathoVax LLC, a vaccine biotechnology startup, where they worked on advancing RGVax, the world's first Universal HPV vaccine.

Dr. Wang has also held multiple roles at Johns Hopkins Medicine, including Adjunct Assistant Professor in Pathology, Postdoctoral Fellow, and PhD Candidate (Margaret Lee Fellow). During their time at Johns Hopkins, they developed a laboratory papillomavirus disease mouse model for HPV vaccines, leading to a top publication in the virology category and a $300K SBIR grant. Joshua Weiyuan also made significant contributions to the field of immunology and vaccinology of Human Papillomavirus (HPV), with 11 published publications and 4 pending.

In addition to their work in biotechnology and healthcare, Dr. Wang has also gained experience in the finance and startup sectors. Joshua Weiyuan served as a VentureLabs Entrepreneuring Fellow at Flagship Ventures and worked as an Equity Research Extern at T. Rowe Price. Joshua Weiyuan was also a Start-Up Leadership Fellow in the DC chapter of the Startup Leadership Program.

Dr. Wang's earlier work experience includes being a Visiting PhD student at the Johns Hopkins Bloomberg School of Public Health and Imperial College London, where they conducted research on preventing substance abuse, HIV, and investigated mycoviruses. Joshua Weiyuan was also a Summer Student Research Assistant at the Singapore Immunology Network, where they studied innate and adaptive immune responses against Chikungunya virus infection.

Overall, Dr. Joshua Weiyuan Wang has made significant contributions to the fields of biotechnology, immunology, and healthcare through their research, leadership positions, and entrepreneurial endeavors.

Joshua Weiyuan Wang Ph.D. obtained their Bachelor of Science (BSc) with First Class Honours in Biology from Imperial College London, where they studied from 2007 to 2010. Joshua Weiyuan then pursued their Doctor of Philosophy (Ph.D.) in Pathobiology at The Johns Hopkins University from 2010 to 2015. In 2015, they received a CORe: Credential of Readiness from Harvard Business School. Additionally, Joshua has obtained several certifications, including "The Language and Tools of Financial Analysis" from The University of Melbourne in September 2015, "Introduction to Marketing" from the University of Pennsylvania in August 2015, "New Venture Finance: Startup Funding for Entrepreneurs" from the University of Maryland in March 2015, and "Clinical Vaccine Trials and Good Clinical Practice" from Johns Hopkins Bloomberg School of Public Health in an unspecified year.